














































MUG	reaction	solution	 (Sigma)	using	a	Wallac	1420D	scanning	multilabel	counter	 (355 nm/460 nm).	β-galactosidase	activity	 (mU)	was	determined	by	means	of	calibration	curve	using	diluted	β-galactosidase	with





















it	was	concluded	 that	modification	of	R6	peptide	with	NLS	module	 improves	 its	DNA-condensation	properties,	due	 to	 the	 increasing	of	 the	carrier’s	positive	charge.	Previously	Siprashvili	with	co-authors	clearly
showed	that	increase	of	cationic	residues	number	in	peptide	carriers	leads	to	augmentation	of	their	DNA-condensing	properties.16









































molecules	completely	neutralize	DNA,	but	addition	of	more	polymer	to	this	neutral	core	 leads	to	the	formation	of	a	shell	of	extra	carrier	molecules	around	the	core	that	results	 in	 formation	of	positively	charged
polyplexes	with	their	highest	gene	transfer	activity.24	In	our	study	we	used	for	transfection	N/P	ratios	≥4	and	it	can	be	suggested	that	NL2	and	NL3	polyplexes	may	differ	from	NL1	and	R6	polyplexes	in	transfection
properties	because	their	neutral	cores	are	formed	at	different	N/P	ratios	(Figs.	1,	2).
According	to	obtained	results	modular	carrier	NL3	with	90 mol%	of	SV40	NLS-modifed	peptide	provided	the	most	efficient	transfection	and	nuclear	uptake	by	non-dividing	cells.	Our	study	proves	the	efficiency
of	cross-linking	peptide	modification	with	nuclear	localization	signal	for	the	gene	delivery	into	non-dividing	cells.
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